The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show
promising results, but drug resistance often limits durable clinical responses. There is a …

BRAF inhibitor therapy may provide profound initial tumor regression in metastatic
melanoma with BRAF V600 mutations, but treatment resistance often leads to disease …

The advent of personalized medicine has ushered in a new era for cancer therapy with a
significant impact on the management of advanced melanoma. Molecular targeted therapies …

BRAF inhibitors were among the first systemic therapies to show clinical benefit in metastatic
melanoma. Here, we review the spectrum of BRAF mutations in melanoma, their role in …

Patients with metastatic melanoma have historically had dismal outcomes. The last several
years has seen the emergence of effective immune and targeted therapies for metastatic …

Almost 50% of metastatic melanoma patients harbor a BRAF V600 mutation andthe
introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors …

Therapy of BRAF-mutant melanoma with selective inhibitors of BRAF (BRAFi) and MEK
(MEKi) represents a major clinical advance but acquired resistance to therapy has emerged …

Metastatic melanoma has historically been considered as one of the most therapeutically
challenging malignancies. However, for the first time after decades of basic research and …

Purpose: BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of
metastatic melanoma in patients with BRAFV600E mutation in their tumors. However, the …

FDA-approved BRAF inhibitors produce high response rates and improve overall survival in
patients with BRAF V600E/K–mutant melanoma, but are linked to pathologies associated …